Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Lisdexamfetamine

Brand: Elvanse®
NICE TA: 
Indication: ADHD in children and young adults
Disease category: Central nervous system
Commissioning responsibility: CCG
PbR excluded: No

Background

Lisdexamfetamine (Elvanse) is recommended for use in the treatment of ADHD in children and young adults only in complex patients who meet both of the following criteria.
• extenuating circumstances exist which mean that a patient would not reliably receive all the required doses of dexamfetamine throughout the day and requires a once daily dose of lisdexamfetamine to support adherence
• treatment has been agreed through the internal governance arrangements of the trust.

Recommendation

LMMG recommendation: Amber1
Click here to find the definitions for the colour classifications

Reason for decision:  Shared care required

Supporting documents:

LMMG New Medicine Recommendation - Lisdexamfetamine In Children And Young Adults (383.1 KiB)

Combined Adult And Child ADHD Share Care Guideline VERSION 1.1 (442.7 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Amber 1

Amber1

Amber1

Amber1

Amber1

Amber1